bioRxivMicrobiology
Systematic measurement of combination drug landscapes to predict in vivo treatment outcomes for tuberculosis
J. Larkins-Ford, T. Greenstein, N. Van, Y. N. Degefu, M. C. Olson, A. Sokolov, B. B. Aldridge
Abstract
A lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis. Variation in Mycobacterium tuberculosis drug response is created by the differing microenvironments in lesions, which generate different bacterial drug susceptibilities. To better realize the potential of combination therapy to shorten treatment duration, multidrug therapy design should deliberately explore the vast combination space. We face a significant scaling challenge in making systematic drug combination measurements because it is not practical to use animal models for comprehensive drug combination studies, nor are there well-validated high-throughput in vitro models that predict animal outcomes. We hypothesized that we could both prioritize combination therapies and quantify the predictive power of various in vitro models for drug development using a dataset of drug combination dose responses measured in multiple in vitro models. We systematically measured M. tuberculosis response to all 2- and 3-drug combinations among ten antibiotics in eight conditions that reproduce lesion microenvironments. Applying machine learning to this comprehensive dataset, we developed classifiers predictive of multidrug treatment outcome in a mouse model of disease relapse. We trained classifiers on multiple mouse models and identified ensembles of in vitro models that best describe in vivo treatment outcomes. Furthermore, we found that combination synergies are less important for predicting outcome than metrics of potency. Here, we map a path forward to rationally prioritize combinations for animal and clinical studies using systematic drug combination measurements with validated in vitro models. Our pipeline is generalizable to other difficult-to-treat diseases requiring combination therapies. One Sentence SummarySignatures of in vitro potency and drug interaction measurements predict combination therapy outcomes in mouse models of tuberculosis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements
J. Larkins-Ford, Y. N. Degefu, … B. B. Aldridge·bioRxiv·Dec 5, 2021
- Transcriptome signature of cell viability predicts drug response and drug interaction for Tuberculosis
V. Srinivas, R. A. Ruiz, … N. S. Baliga·bioRxiv·Feb 9, 2021
- Transcriptomic signatures predict regulators of drug synergy and clinical regimen efficacy against Tuberculosis
Shuyi Ma, Suraj Jaipalli, … Sriram Chandrasekaran·mBioPeer-reviewed·Nov 11, 2019
- A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs
Joseph M. Cicchese, Awanti Sambarey, … Sriram Chandrasekaran·Scientific ReportsPeer-reviewed·Mar 11, 2021
- Use of Multiple Pharmacodynamic Measures to Deconstruct the Nix-TB Regimen in a Short-Course Murine Model of Tuberculosis
M. A. Lyons, A. Obregon-Henao, … G. T. Robertson·bioRxiv·Nov 8, 2023
- Nonclinical pharmacokinetics and relative efficacy of the first 25 novel tuberculosis drug combinations from the PAN-TB consortium: Use of the BALB/c relapsing mouse model and combination pharmacokinetics within a modeling-based framework
Sylvie Sordello, Alessia Tagliavini, … Anna M. Upton·bioRxiv·May 7, 2026